

LEPTIN—MUCH MORE THAN A SATIETY SIGNAL

Ruth B. S. Harris

*Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808;
e-mail: harrisrb@pbrc.edu*

Key Words insulin, reproduction, stress

■ **Abstract** Much attention has focused on the effects of leptin as a central satiety agent. There is now a significant amount of evidence that leptin is active in the periphery. This review focuses on the ability of leptin to modify insulin sensitivity, tissue metabolism, stress responses, and reproductive function. Leptin's effect on several of these systems is mediated via the hypothalamic-pituitary axis. Therefore, although *in vitro* studies provide evidence for direct effects on specific tissues and metabolic pathways, it is essential to consider the interactions between leptin and other regulatory factors *in vivo*. Little is known about the regulation of peripheral receptor expression or the production of binding proteins. Both of these factors determine the bioactivity of circulating leptin and have the potential to induce a peripheral resistance to leptin, similar to the central "leptin resistance" observed in obese subjects. Future research will clarify which of the endocrine and metabolic actions of peripheral leptin are of physiological relevance and which should be considered a pharmacological manipulation.

CONTENTS

INTRODUCTION	46
THE RELATIONSHIP BETWEEN LEPTIN, INSULIN, AND INSULIN SENSITIVITY	47
The Effect of Leptin on Insulin Secretion	47
The Effect of Insulin on Leptin Expression and Secretion	48
The Relationship Between Leptin and Insulin Sensitivity	49
LEPTIN AS A GROWTH FACTOR	50
Leptin and Cell Proliferation	50
The Relationship Between Leptin and Growth Hormone	51
Tissue-Specific Effects of Leptin on Energy Utilization	52
LEPTIN AND STRESS	54
Leptin and the Hypothalamic-Pituitary-Adrenal Axis	54
Leptin and the Inflammatory Response	56
Leptin and Energetic Stress	58
Leptin and the Hypothalamic-Pituitary-Thyroid Axis	58
LEPTIN AND REPRODUCTIVE FUNCTION	59
Leptin and the Hypothalamic-Pituitary Gonadal Axis	59

Leptin as a Signal for Sexual Maturation	60
Leptin During Pregnancy	61
CONCLUSIONS	62

INTRODUCTION

In 1953, Kennedy (116) proposed that body energy stores were regulated by a fat-derived, lipostatic, negative feedback signal acting centrally to inhibit feeding. The presence of such a factor was confirmed by parabiosis when the normal partners of hypothalamically lesioned, obese rats stopped eating and lost weight (99). Parabiotic partners share a common blood supply, and manipulation of one parabiont causes a response in the partner if circulating factors are an essential component of the activated pathway. Parabiosis identified mouse mutations that abolished the signal (*ob/ob* mice) or caused insensitivity to the signal (*db/db* mice) (53, 54). In 1994, leptin was identified as the mutated protein in *ob/ob* mice (240). The leptin receptor has multiple isoforms but only the subtype with a long intracellular domain (*Ob-Rb*) was considered to be capable of signal transduction (42). In *db/db* mice, an early stop codon renders *Ob-Rb* unresponsive (42). Many investigators have focused on leptin's function as a satiety signal. It is clear, however, that leptin can modulate, or regulate, multiple systems.

Leptin is expressed in the stomach (6), placenta (138), and muscle (230) but adipose tissue is the primary source of circulating leptin (240). The positive correlation between percentage of body fat and circulating leptin (57) and the profound anorexia caused by centrally administered protein (232a) support leptin's role as a lipostatic factor. In contrast, increasing peripheral leptin, by infusion or adenovirus-mediated expression, causes only a transient reduction in food intake (95, 127, 140), and high levels of leptin in obesity fail to inhibit food intake (57). Obese *ob/ob* mice are an exception, showing a sustained sensitivity to leptin (95, 140, 175). The dissociation between circulating leptin and satiety in other forms of obesity has been attributed to rate-limited transport of leptin across the blood brain barrier preventing activation of hypothalamic *Ob-Rb* receptors (35). However, short-form leptin receptors (*Ob-Ra*), putative transport proteins at the blood-brain barrier, increase with high-fat feeding (19) even though diet-induced obesity leads to "leptin resistance." Regulation of receptor expression (16) may be an important determinant of leptin sensitivity, as it has been reported that leptin is expressed in the brain (159). Resistance has been attributed to a postreceptor inhibitor of signaling (*SOCS3*), but leptin elevates this inhibitor in *ob/ob* mice (18), which do not become resistant (95, 140, 175).

Because leptin is secreted by adipocytes and the satiety response to peripheral leptin is transient (95, 140), the protein may have primary functions unrelated to satiety. This review focuses on leptin action in the periphery, examining its relationship with insulin, nutrient utilization, the stress response, and reproductive function.

THE RELATIONSHIP BETWEEN LEPTIN, INSULIN, AND INSULIN SENSITIVITY

The Effect of Leptin on Insulin Secretion

Leptin expression and secretion correlate with percentage of body fat (57). Obesity increases risk for insulin resistance and subsequent non-insulin-dependent diabetes. There is also substantial evidence for a direct interaction between leptin and insulin. Pancreatic islets express both Ob-Rb and Ob-Ra receptors (74, 104), with Ob-Ra accounting for 75%–90% of the population (104, 172). The receptors are present on insulin secreting β -cells and somatostatin δ -cells but not glucagon-containing α -cells (117). Investigation of the effect of leptin on insulin secretion *in vitro* has produced variable results. One study found that physiological concentrations of leptin stimulated basal insulin release from rat islets and a β -cell pancreatic cell line but had no effect on glucose-stimulated release (212). Others found no change in basal or glucose-stimulated insulin secretion from perfused rat pancreas (134, 179) or from islets from ob/ob mice exposed to higher concentrations of leptin (45). In contrast, a majority of reports demonstrate inhibition of insulin secretion by leptin. In human islets and a mouse insulinoma cell line, low concentrations of leptin rapidly inhibited basal insulin release (129). However, rat islets only responded in hyperglycemic conditions. There was a U-shaped response, with inhibition of insulin release by 10 nM leptin but not by 1 or 100 nM leptin (172). In genetically obese rodents, leptin inhibited insulin release from islets and pancreas of ob/ob mice but not db/db mice or the leptin-insensitive fa/fa Zucker rat, implicating Ob-Rb in the response (74, 117). Despite the presence of receptors on δ -cells, leptin had no effect on somatostatin release (117).

The discrepancies between studies may be attributed to different leptin preparations or involvement of multiple signaling pathways controlling Ca^{2+} flux. Islets from ob/ob mice are hypersensitive to acetylcholine (43) and glucose and are hyperpolarized because of abnormal regulation of ATP-sensitive K^{+} channels (186). In these islets, leptin activated K^{+} channels to increase membrane conductance (117) by an insulin-sensitive phosphatidylinositol-3 kinase (PI-3K)–dependent mechanism (96) that may be specific for ob/ob mice, as there is no effect of leptin on K^{+} channels in rat islets (171, 179). Leptin also reversed the hypersensitivity to acetylcholine (43) by inhibiting activation of protein kinase C (44). Protein kinase C and cAMP-protein kinase A are also inhibited in rat islets (171, 179). In islets from neonatal rats and a pancreatic cell line, leptin inhibited glucose-stimulated insulin secretion, increased phosphodiesterase 3B activity, and increased PI-3K activity fivefold. The inhibition of insulin secretion was blocked by either phosphodiesterase or PI-3K inhibitors (241).

The relevance of *in vitro* observations to the *in vivo* situation remains to be determined. Leptin reverses hyperinsulinemia in ob/ob mice, but at higher concentrations than are required for normoglycemia (175), which suggests improved insulin sensitivity. We demonstrated an inhibition of glucose-stimulated insulin

release in leptin-treated mice (94), but others have shown that depletion of intracellular triglycerides in hyperleptinemic rats prevents normal islet function (127, 198). Therefore, inhibition of insulin release *in vivo* may be secondary to the metabolic state of the islets, rather than a direct action of leptin. The *in vitro* studies examined acute responses, when insulin secretion was determined by intracellular calcium. Extended exposure to leptin has been reported to inhibit insulin mRNA expression (172); however, there is no evidence for insulin insufficiency *in vivo*. Twelve months of leptin treatment caused weight loss but did not correct hyperinsulinemia in a human subject with congenital leptin deficiency (79), and in normoglycemic subjects, there was a positive correlation between fasting concentrations of leptin and insulin (90, 243), independent of body mass index (BMI) or waist-to-hip ratio.

The Effect of Insulin on Leptin Expression and Secretion

In rats, there is a diurnal cycle of leptin expression, with a nocturnal peak that is abolished by food deprivation but is restored within 4 h of refeeding (191). The stimulation of leptin is insulin dependent, as food deprivation does not change already low levels of leptin expression in insulin-deficient streptozotocin-treated rats (174), but insulin replacement rapidly restores leptin to normal (146). In fasted mice and rats, injections of glucose or insulin rapidly stimulate leptin expression (157, 191), but there is no effect in hyperinsulinemic mice (157). In humans, the nocturnal rise in circulating leptin shifts when meal times are delayed (193), even though food intake has no immediate effect on leptin concentrations (57, 147).

In vitro, pharmacological concentrations of insulin caused a rapid, but transient, stimulation of leptin expression and secretion by rat adipocytes (10). Hyperinsulinemia increased leptin mRNA expression in human adipocytes after 72 h, but this was reversed by 96 h even though leptin release remained elevated (124). Others reported an increase in leptin expression in human adipocytes exposed to insulin, and the response was substantially augmented by the presence of cortisol, which suggests that the two hormones could act synergistically during the development of obesity (227). Insulin promotes transcription of the leptin gene (139) and relocation of intracellular protein from the endoplasmic reticulum toward the cell membrane (10), but the delayed response may be secondary to a tropic effect of insulin on adipocytes, providing an *in vitro* model of overfeeding (124). This concept is supported by observations that the increase in leptin expression was prevented by blocking glucose transport (163).

In vivo, the time course of insulin stimulation of leptin is dose dependent. During a hyperinsulinemic, euglycemic clamp, using a pharmacological level of insulin, leptin concentrations in rats increased within 2 h. When insulin represented only three times the basal concentration, leptin expression was doubled after 2 days in one experiment (62) and in another plasma leptin was not increased until day 5 (126). In human subjects with a wide range of body fat content and insulin sensitivity, hyperinsulinemic, euglycemic clamps of short duration (2–5 h) show no effect of insulin on leptin (65, 124, 132). An acute response was initiated only

when circulating insulin increased from 32 to 823 pmol/liter (217). In two studies with 9-h infusions, serum leptin progressively declined in a saline control group, whereas infusions that tripled fasting insulin and inhibited lipolysis prevented the fall in leptin, and high concentrations of insulin increased leptin (148, 189). This effect could not be attributed to a change in free fatty acids (FFA), as there was no response to a FFA infusion with normal levels of insulin (20). Moderate amounts of insulin stimulate leptin when the hyperinsulinemia is maintained for several days (20, 124), indicating that, under physiological conditions, insulin does not have a direct effect on leptin expression and secretion. It is more likely that hyperinsulinemia promotes fat deposition, which subsequently increases leptin expression. However, one piece of *in vivo* evidence supports a chronic regulatory effect of insulin on leptin production. Insulinoma patients were hyperinsulinemic, hypoglycemic, and hyperleptinemic compared with BMI-matched controls, until their tumors were removed, when insulin and leptin returned to normal levels (64).

The Relationship Between Leptin and Insulin Sensitivity

During an extended hyperinsulinemic clamp, the diurnal rhythmicity of leptin release was exaggerated and cyclic changes in leptin and insulin resistance were synchronized but opposite, implying that leptin caused insulin resistance (20). Additionally, in healthy children and adults (90, 111, 132, 243), obese individuals (110, 111), or those who have insulin-dependent or non-insulin-dependent diabetes (65), there is a positive correlation between fasting leptin and insulin concentrations, independent of body fat content. Two studies (3, 132) demonstrated a significant correlation between fasting leptin and insulin resistance in healthy postmenopausal women after controlling for body fat content. Leptin correlates with islet secretion of insulin and glucagon in fasting conditions, in response to arginine, and with insulin released in response to a glucose challenge. In contrast, there is no correlation with secretion of a third islet protein, pancreatic polypeptide, or with glucagon secreted during hyperglycemia. These results led to the suggestion that leptin may be a signal from adipocytes to islets to hypersecrete insulin when fat content is increased and insulin sensitivity is lowered (132). The relationship between leptin and islet secretory function is lost in subjects in whom islet compensation for insulin insensitivity has failed (132), and leptin is inappropriately low in subjects with poorly controlled diabetes and deterioration of β -cell function (48).

The positive correlation between leptin and insulin secretion *in vivo* is in direct opposition to evidence of inhibition of insulin secretion *in vitro*, which suggests an overriding influence of additional regulatory factors *in vivo*. The relationship between leptin and insulin is further confused by the effect of exogenous leptin on insulin sensitivity in experimental animals. We demonstrated that insulin release in response to a glucose challenge was exaggerated 2 h after a leptin injection but was blunted in mice infused with leptin for 5 days (94). In *ob/ob* mice, which are

hypersensitive to leptin (95, 140), leptin treatment reverses hyperglycemia before there is any change in insulin or body weight, indicating either improved insulin sensitivity or that leptin has insulin-like activity (175). In support of the latter concept, high-dose leptin infusions in insulin-depleted and insulin-resistant streptozotocin rats prevented weight loss, normalized fasting glucose, and increased whole body glucose utilization during a hyperinsulinemic clamp (46). Lower doses of leptin partially normalized blood glucose and prevented hyperphagia (203). Obviously, a great deal more work is needed to clarify the relationship between leptin and insulin sensitivity, in both pharmacological and physiological conditions.

LEPTIN AS A GROWTH FACTOR

Leptin and Cell Proliferation

A majority of immune and blood cells are derived from undifferentiated hematopoietic stem cells that are found in the yolk sac, spleen, and bone marrow of the fetus. In adults, they are only in bone marrow, which also contains adipocytes. Primary culture of human bone marrow stromal cells showed that the adipocytes express exceptionally high levels of leptin (130), which plays a direct role in hematopoiesis. The adipocytes require glucocorticoids to differentiate but do not respond to insulin and do not express either β 3-adrenergic receptors or UCP1 (130). Leptin receptors Ob-Ra, Ob-Rb, and a novel leptin receptor, with an intermediate-length cytoplasmic domain, are found in fetal stem cells (14, 47). In cell culture, leptin stimulated proliferation of stem cells, acting synergistically with other growth factors (14). An essential role for leptin in cell proliferation *in vivo* was demonstrated by abnormal erythropoiesis and lymphopoiesis in db/db mice (14), and by overexpression of leptin receptors in cells from patients with myeloid leukemia but not lymphoid leukemia. In these cells, leptin enhanced proliferative activity of other cytokines, such as IL-3, and inhibited apoptosis (125).

In a line of human marrow stromal cells, leptin did not change proliferation but promoted differentiation of osteoblasts and increased mineralization of matrix proteins with no effect on adipocyte differentiation (215). *In vivo*, there was a positive correlation between leptin and periosteal envelope expansion in premenarchal girls (154) and an inverse relationship between adipocytes and osteoblasts in osteoporesis (215); however, there was no correlation with markers for bone formation or resorption in adult women (184). This suggests that leptin has a role in bone formation during growth but is less important in maturity. In addition to its effect on hematopoietic cells, leptin stimulated proliferation of pituitary cells (109) of a pancreatic β -cell line (211) and in a mouse embryonic cell line (208). Leptin has been reported to promote angiogenesis (201) and may also be necessary for normal brain development (1). Proliferation is associated phosphorylation of mitogen-activated protein kinase (208, 211). Thus, the proliferative activity of leptin is not limited to a particular cell type and is mediated by postreceptor proteins that are also responsible for insulin's mitogenic activity.

The Relationship Between Leptin and Growth Hormone

Pituitary-derived growth hormone (GH) plays a key role in determining body composition. Pulsatile release of GH from the hypothalamus is stimulated by growth hormone releasing hormone (GHRH) and inhibited by somatostatin (SRIH). Many effects of GH are mediated by circulating insulin-like growth factor-1 (IGF-1), which is secreted from the liver under control of GH. IGF-1 inhibits hypothalamic GH release, and its bioactivity is regulated by circulating binding factors 1–6. In obesity, GH is suppressed and the response to pharmacological interventions that promote GH release is also blunted (192).

The inverse relationship between adiposity and GH implies that adipose-derived factors regulate GH secretion. Leptin receptors colocalize with GHRH-containing neurons in the arcuate nucleus of the hypothalamus (91) and have been identified in pituitary tissue (109, 199). However, any effect that leptin has on GH secretion appears to be mediated by hypothalamic neuropeptide Y (NPY). *In vitro*, high concentrations of leptin did not change basal or GHRH-stimulated GH release from anterior pituitary cells (50), whereas *in vivo*, central [intracerebroventricular (i.c.v.)] administration of a leptin antibody decreased the amplitude of pulsatile GH release in fed rats, and leptin restored GH release, but not IGF-1 expression, in fasted animals (36, 225). In fed rats, i.c.v. leptin stimulated pituitary GH and hypothalamic GHRH mRNA expression, inhibited hypothalamic expression of SRIH and NPY (50, 225), enhanced responsiveness to GHRH, and augmented GH secretion (213). It has been shown that NPY stimulates SRIH and inhibits GH release (185); therefore, leptin stimulation of GH is probably mediated by a down-regulation of NPY (225).

When considering the influence of GH on leptin secretion, GH infusions had no effect on leptin expression in hypophysectomized rats, although IGF-1 suppressed already-low levels of expression (22). In contrast, leptin expression was inhibited, without any change in fat mass, in fa/fa rats injected with GH for 7 days (106). This response could not be replicated by infusing IGF-1 (105), although high doses of IGF-1 reduced fat pad weight and leptin in normal rats (23). These studies indicate that GH acts indirectly, possibly through IGF-1, or by influencing insulin release and cell metabolism. The indirect relationship is also evident in human subjects. In prepubertal children given a GH stimulation test, leptin was inversely related to peak GH release, independent of body fat content (60). In both young and adult GH-deficient subjects, 4 weeks of GH replacement did not change leptin (169), which was elevated in parallel with body fat content. Despite the lack of response to sustained treatment, GH acutely stimulated leptin in GH-deficient subjects (169) and critically ill patients (218), but the change in leptin correlated with insulin or IGF-1, which has insulin-like activity (218). In contrast, GH treatment of obese men with IGF-1 deficiency temporarily stimulated energy expenditure and suppressed leptin (114). Therefore, there is little evidence that GH has a direct effect on leptin expression or secretion, although, via inhibition of hypothalamic NPY expression, leptin increases the tone of the GH axis. Thus, in the obese or

“leptin-resistant” state, inhibition of hypothalamic leptin receptor activity could suppress GH secretion. It has been reported that chronic exposure to high levels of GH increases pituitary expression of Ob-Rb (32); therefore, inhibition of GH in obesity could produce a reciprocal insensitivity to leptin.

Tissue-Specific Effects of Leptin on Energy Utilization

Weight loss in leptin-treated animals is almost exclusively from loss of adipose tissue, and correction of leptin deficiency reduces fat and causes a small decrease in body water but retains protein (79, 140, 175). This contrasts with loss of lean mass and preservation of fat during food restriction or stress (242). Little is known about the mechanisms protecting muscle mass. In a cell line of C₂C₁₂ myotubules, which express only Ob-Ra receptors (17), leptin had no effect on protein synthesis but caused a small inhibition of protein breakdown (182). In the same cells, leptin produced a temporary protein kinase C- and PI 3K-dependent increase in basal glucose uptake and a sustained PI-3K-dependent increase in glycogen synthesis (17). Examination of proteins common to signal transduction for both insulin and cytokines indicated association of PI-3K with insulin receptor substrate-2 (IRS-2) (115) but not IRS-1 (17). There was also increased binding of PI-3K with janus kinase 2 (JAK2) but not JAK1. Therefore, leptin may augment, or mimic, insulin signaling downstream of PI-3K (115).

Cultured skeletal muscle cells express Ob-Rb receptors (165) and do not respond in the same manner as C₂C₁₂ myotubules (183). Leptin stimulated glycogen synthesis in muscle from ob/ob mice (143) but had no effect in muscle from lean mice or rats (143, 165). High concentrations of leptin inhibited triglyceride synthesis and stimulated fatty acid oxidation, whereas physiological concentrations caused only small changes in lipid metabolism (165). Despite this minimal response *in vitro*, *i.c.v.* or peripheral leptin infusions increased muscle glucose uptake and glycogen content in mice and rats (63, 112). These responses were mediated centrally, as denervation blunted the response in oxidative muscle and abolished it in glycolytic muscle (112). Recently, it was reported that glucosamine, the product of muscle hexosamine synthesis and an index of energy availability, or feeding a high-fat diet (231) induced leptin expression in skeletal muscle, stimulated adipose leptin expression, doubled circulating leptin, and induced peripheral insulin resistance (230). Therefore, if leptin stimulates fatty acid oxidation, it may regulate muscle metabolism to match nutrient availability.

The specific loss of fat in leptin-treated animals is caused by inhibition of lipogenesis and promotion of fatty acid oxidation. Experiments involving gold thioglucose-lesioned mice or transplantation of fat into hyperleptinemic rats indicate that neural input is not essential for leptin action on adipocytes (30, 234), which express both Ob-Rb and Ob-Ra receptors (118). Several investigators found no effect of leptin on glucose uptake or lipolysis in adipocytes or 3T3-L1 cells (155, 183). In contrast, Muller et al (164) reported that a 6-h exposure to leptin inhibited insulin action in cultured adipocytes. Inhibition was reversible and

specific, as there was no change in vanadate stimulated lipogenesis. The inhibition of glucose transport (239) and lipogenic enzymes (232) has been confirmed in adipocytes and in a preadipocyte cell line transfected with the leptin gene (7). The response to leptin is faster in pieces of adipose tissue (200) and in vivo (30, 84) than in vitro, and the acute response to leptin in isolated adipocytes is different from that in cells from leptin-treated mice (94), implying mediation by intermediary paracrine factors. Glycerol release from leptin-treated adipocytes has been interpreted as a stimulation of lipolysis (164); however, circulating FFAs are not elevated in hyperleptinemic rats (198) because they are oxidized and not released from adipocytes (232). Leptin does not stimulate glycerol release in adipocytes from db/db mice (84) or fa/fa rats (232), implicating Ob-Rb in the response. Some of the fat loss can be attributed to uncoupling proteins (UCP), which dissociate oxidative metabolism from ATP synthesis, as discussed elsewhere (127a). UCPs were decreased in fat, muscle, liver, and brown adipose tissue of mice pair fed to leptin-treated animals, but i.c.v. leptin prevented the down regulation in all tissues, favoring energy expenditure in a situation of reduced energy intake (63).

Whole-body glucose turnover is stimulated by leptin, primarily through regulation of hepatic glucose metabolism. Infusion (i.c.v. or peripheral) of leptin into conscious mice increased glucose turnover, promoted glucose uptake into muscle and brown fat, reduced liver glycogen content, and doubled whole-body glycolysis (112). In a similar study, low concentrations of leptin-infused i.c.v. did not change insulin-stimulated glucose clearance or glycolysis, but it inhibited hepatic glycogen synthesis and stimulated glucose production by stimulating phosphoenolpyruvate carboxykinase (PEPCK), the rate-limiting enzyme in gluconeogenesis. The ratio of glycolysis to gluconeogenesis determines the malonyl CoA concentration, which is rate limiting for triglyceride reesterification; therefore, leptin would promote fatty acid oxidation by inhibiting triglyceride formation (187). Identical responses were obtained with a β 3-adrenergic receptor antagonist, implying that the sympathetic nervous system mediated the changes in hepatic glucose production (142). Peripheral leptin produced similar effects (187), possibly by acting centrally. In contrast, leptin inhibited PEPCK expression in ob/ob mice (31). This may have been secondary to inhibition of arcuate nucleus NPY expression (195), which would have the same end result (153).

The studies described above infused leptin for periods of hours, but extended treatment produces a different hepatic response. Eight days of peripheral leptin infusion reduced adiposity and enhanced insulin action, compared with pair-fed rats. Whole-body and liver glycogen synthesis were increased, as was hepatic glycolysis, but glucose production was reduced because of almost total inhibition of glycogenolysis despite increased PEPCK expression and gluconeogenesis (12). In a second study, which compared rats that lost weight during food restriction or during infusion of either leptin or a β 3-adrenergic receptor agonist for 8 days, only leptin stimulated glycolysis, gluconeogenesis, and PEPCK expression (11). In addition, glycogen was preserved longer in fasted hyperleptinemic rats than in control rats, and glycogen accumulated faster following glucose injection

(170). Thus, chronic treatment with exogenous leptin promotes glucose oxidation and maintenance of glycogen stores simultaneously, while stimulating fatty acid oxidation and inhibiting lipid accumulation in adipose tissue.

Although changes in liver metabolism may be initiated, in part, in the brain, there is evidence for a direct effect on hepatocytes. In human hepatoma cells that express Ob-Rb, leptin rapidly inhibited phosphorylation of IRS-1 but increased its association with PI-3K. In a rat hepatoma cell line, leptin stimulated PEPCK expression and partially reversed insulin inhibition, similar to the response *in vivo* (51). In a different study, using rat cells transfected with Ob-Rb cDNA, leptin did not phosphorylate IRS-1 or IRS-2 or increase association of PI-3K with IRS-1, but it did increase PI-3K binding to IRS-2 and activated STAT3. These responses were not replicated in human hepatoma cells transfected with Ob-Rb cDNA (233), illustrating the limitations of cell lines that do not contain all of the signaling machinery present in hepatocytes. In an isolated liver preparation, perfusion with insulin or leptin inhibited glucose production, but, in glycogen-depleted livers, leptin increased glycogen synthesis and increased lactate uptake (167). Cohen et al (52) compared livers from leptin-treated *ob/ob* mice with those exposed to leptin *in vitro*. *In vivo* treatment caused a much greater increase in glycogen synthesis and inhibited fatty acid synthesis, whereas fatty acid synthesis was stimulated *in vitro*. These results demonstrate that leptin influences hepatic metabolism directly, by modifying tissue enzymes, and indirectly, by changing neural and hormonal input to the organ.

LEPTIN AND STRESS

Leptin and the Hypothalamic-Pituitary-Adrenal Axis

Stress responses are initiated by activating corticotrophin releasing factor (CRF), which recruits endocrine, immune, neural, and neurochemical systems. The type and degree of stress determines the outcome, but consistent responses are stimulation of the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system (SNS). Leptin has been shown to modulate HPA axis activity (97), SNS activity (55), and release of proinflammatory cytokines (81), implying that it has the potential to modify the stress response (24, 97). However, evidence for this is inconsistent. Third ventricle infusion of leptin at the start of the dark period, when leptin is low and corticosterone is rising, caused a delayed but extended stimulation of corticosterone, insulin, and leptin (219). In contrast, a peripheral injection of leptin blunted the corticosterone and adrenocorticotrophic hormone (ACTH) response to food deprivation or immobilization stress (2, 97), but this was not replicated with infusion of smaller quantities of leptin (103). *In vitro*, leptin inhibited CRF release from hypoglycemic hypothalamic tissue (97), but CRF release from perfused tissue was stimulated within 15 min (181) and ACTH release from perfused pituitary tissue increased after 45 min (181). These conflicting results may be attributed to experimental conditions, or they may demonstrate that leptin

inhibits stress-induced release of CRF and corticosterone but maintains tone of the HPA axis in nonstress conditions.

Arcuate nucleus proopiomelanocortin (POMC) expression is suppressed in *ob/ob* and *db/db* mice and is stimulated by leptin in *ob/ob* mice and in fasted rats (158, 196). POMC is the precursor for several peptides, including β -endorphin, which inhibits hypothalamic CRF release, and α -melanocyte-stimulating hormone, which contributes to the regulation of food intake, immune function, and aspects of reproduction. Leptin increases POMC expression but it is not known whether posttranscriptional control promotes production of specific peptides. Wand et al (229) proposed that leptin inhibited the HPA axis via release of β -endorphin, which inhibits hypothalamic CRF secretion. Thus, chronic exposure to leptin would down-regulate the response to stress by increasing opioid tone.

In contrast to stimulation of CRF and ACTH release, leptin inhibits glucocorticoid release from the adrenal cortex *in vitro*. Leptin receptors, a majority of which are Ob-Ra (33), have been identified in adrenal medulla and cortex (33, 86). Autoradiographs show dense leptin binding to the medulla but not the cortex, correlating with receptor distribution (86). Leptin produces a dose-dependent inhibition of basal and ACTH-stimulated cortisol secretion in cultured adrenal cells (26, 86), by inhibiting enzymes in the steroid synthetic pathway (86). Leptin exerts an equal, or greater, inhibition of aldosterone but has no effect on catecholamine release from cultured adrenal chromaffin cells in either basal or ACTH-stimulated conditions (86), except when excessive concentrations of leptin are used (209). Stimulation of CRF and ACTH secretion with an inhibition of glucocorticoids would permit leptin to accentuate central actions of CRF independent of an HPA endocrine response. Additionally, the balance between SNS and glucocorticoid activity within the adrenal gland determines the concentrations of neurotransmitters, cytokines, and growth factors that modulate hormone release (27).

Glucocorticoids are more potent regulators of leptin than either CRF or ACTH. *In vitro*, dexamethasone and cortisol stimulated leptin expression in adipocytes (56, 204, 227). In incubated adipose tissue, leptin secretion correlates with adipocyte size and is greater in subcutaneous than omental fat (220) and in fat from women than from men (37). Fat from obese subjects gives an exaggerated response to dexamethasone because of increased sensitivity rather than increased receptor binding (92). In one study, both dexamethasone and insulin stimulated leptin expression in visceral and subcutaneous fat (92). The response was partially prevented by inhibiting translation or by hyperinsulinemia and was totally blocked by inhibiting protein synthesis (92). Another study (188) found depot-specific responses in fat from obese subjects. Leptin mRNA expression was transiently stimulated by dexamethasone in both subcutaneous and omental fat and was augmented by insulin but blocked by a transcription inhibitor. However, leptin secretion increased only in subcutaneous tissue. Thus, insulin and glucocorticoids may work in concert to promote leptin release in conditions such as obesity, but the magnitude of response may be determined by the size of specific fat depots.

In vivo, daily injection of glucocorticoids, at doses that inhibited food intake and weight gain, increased leptin expression fourfold in rats (68), but a 3-week infusion caused weight loss and inhibited expression, indicating that fat mass is the primary determinant of leptin expression. Replacement of corticosterone in adrenalectomized rats prevented a drop in leptin expression but had no effect in sham-operated rats (210). In contrast, dexamethasone doubled leptin expression and circulating leptin in humans (66, 156, 173). Although these experiments were criticized for using pharmacological doses of dexamethasone (216), others have shown a 50%–100% increase in circulating leptin within 24 h of administration of a physiological dose of cortisol (168) or dexamethasone (73, 173). With continued administration, leptin returned to baseline (168), which suggests that it facilitates the early stages of a chronic stress response, whereas the 24-h delay implies that acute stress would have no effect on leptin release.

Despite experimental evidence, the in vivo leptin response to stress is minimal. A variety of situations that activate the HPA axis, or chronically elevate cortisol, show no correlation between leptin and glucocorticoid concentrations. There is no evidence of inappropriate levels of leptin in Cushing's patients (141). Similarly, activation of the HPA axis by CRF (141), by CRF and arginine vasopressin (223), or by opioid blockade (229) has no effect on leptin, despite substantial elevation of ACTH and corticosterone. Additionally, an ACTH challenge had no effect on leptin (229), indicating that the inverse relationship between diurnal rhythms of ACTH and leptin release were not due to ACTH inhibiting leptin secretion (141). Torpy et al (216) suggest that leptin secretion responds only to inappropriately high doses of synthetic glucocorticoids. However, glucocorticoid release is normally pulsatile and any event that elevates glucocorticoids also activates other systems, such as the SNS, that may antagonize stimulation of leptin expression and secretion.

Leptin and the Inflammatory Response

The inflammatory response includes activation of the HPA axis, cytokine mediated fever, protein catabolism, hypoglycemia, and hypoinsulinemia. Involvement of leptin is not surprising, as it has the tertiary structure of a long-chain helical cytokine (238), and Ob-Rb belongs to the family of class I cytokine receptors (214). However, signal transduction by Ob-Rb is distinct, as it does not oligomerise with gp130 or leukemia inhibitory factor receptor (166). In HepG2 cells transfected with the Ob-Rb gene, leptin caused phosphorylation of signal transducer and activation of transcription (STAT) factors and induced gene expression through interleukin-6 (IL-6) response elements (13). These results demonstrate that leptin has cytokine activity in cells that express appropriate postreceptor signaling proteins and response elements.

Impaired T-cell immunity in ob/ob and db/db mice provides evidence for leptin's involvement in immune function (39, 80). In both genotypes, there is a diminished in vivo response to cell-mediated and humoral challenges (39, 80). Leptin may also provide the link between immunosuppression and malnutrition, as it

reversed starvation-induced suppression of cellular immune responses (145). In the cell-mediated immune response, antigens are presented to T-cells, which release lymphokines that activate macrophages. T-cells, rather than antigen presenting cells, responded to leptin by showing an increased rate of proliferation and production of proinflammatory cytokines (145). In addition to this indirect activation of macrophages, leptin acted directly via Ob-Rb receptors to increase the number of macrophages showing phagocytic activity (85, 144). It did not stimulate cytokine production directly, but enhanced endotoxin-induced production of tumor necrosis factor α (TNF α), IL-6, and IL-12 by a posttranscriptional mechanism (144).

In vivo, leptin normalized the hypersensitivity of ob/ob mice to the endotoxin lipopolysaccharide (LPS) but did not increase resistance in lean mice. The protective effect must be mediated by Ob-Ra, as db/db mice have a normal sensitivity to LPS (76). fa/fa rats are insensitive to leptin and showed a suppressed cytokine response to an LPS challenge; however, there was increased liver damage, attributed to cytokines that sensitize hepatocytes to TNF α and to decreased phagocytic activity by Kupffer cells (236). Many responses to LPS are mediated by TNF α , which is lethal for ob/ob and db/db mice at doses lower than that for lean mice. Leptin normalized sensitivity in ob/ob mice but did not increase resistance in lean mice (207). The protective effect of leptin may be dependent on stimulation of POMC and subsequent release of α -melanocyte-stimulating hormone and glucocorticoids, both of which inhibit TNF α activity (207). Alternatively, it may be attributed to uncoupling proteins. LPS inhibited UCP-2 expression and doubled superoxide anion production in peritoneal macrophages (59), affecting the binding of oxidative-sensitive transcription factors to DNA. Macrophages from ob/ob mice had low levels of UCP-2 expression, high rates of superoxide anion production, and increased binding between the oxidative-sensitive transcription factor C/EBP- β and DNA.

In addition to leptin promoting secretion of inflammatory cytokines, LPS stimulates leptin expression and secretion, despite a simultaneous inhibition of food intake (89). The leptin surge that followed LPS injection initially correlated with inflammation and peaked at 12 h but was reversed within 48 h (160). Two proinflammatory cytokines, TNF α and IL-1 β , mediated this response. TNF α stimulated leptin expression and secretion from adipocytes in vitro and increased circulating leptin in vivo (81). Adipocytes from TNF α knockout mice have increased levels of leptin expression but reduced circulating concentrations of protein, implying that TNF α actively stimulates leptin secretion (119). The stimulatory effect of IL-1 β has been demonstrated in vivo using turpentine inflammation, which promotes secretion of IL-1 β and IL-6 but not TNF α or IL-1 α . Turpentine and LPS induced adipose leptin expression and increased serum leptin concentrations in wild-type and IL-6 knockout mice but had no effect in IL-1 β knockouts (75). These results suggest that TNF α is an intermediary, promoting IL-1 β , which is responsible for the stimulation of leptin. Cytokine-induced expression of leptin in humans has to be confirmed. Leptin was elevated in patients with acute sepsis, and survivors had

higher average levels of leptin than those who did not survive (25), but leptin was normal in patients who had been septic for at least 14 days (34). In cancer patients given daily infusions of IL-1 α (107) or TNF α (244), leptin stimulation was transient. Therefore, the positive feedback loop between leptin and inflammatory cytokines may augment early responses to infection, but leptin is not important in the sustained immune response.

Leptin and Energetic Stress

Starvation, or energy restriction, is associated with a greater fall in leptin than can be accounted for by loss of fat mass (235), especially in women (71). During food restriction, leptin correlated negatively with a metabolic index that represented decreased glucose availability and increased lipolysis (71), which suggests that it was regulated by the metabolic state of cells. When the fall in glucose and insulin during food restriction was prevented (21), or if glucose was infused to prevent ketogenesis (123), circulating leptin concentrations did not change. On the other hand, ketone infusion did not inhibit leptin concentrations (123). Therefore, inhibition of leptin during fasting may be associated with adipocyte metabolism but is not directly caused by ketosis (123). This hypothesis is supported by observations that leptin fell rapidly during exercise in fasted subjects (122) and in type 1 diabetics during insulin withdrawal (4), situations that are metabolically stressful to adipocytes.

In other situations of negative energy balance the effects are inconsistent. Infusion of a β -agonist stimulated lipolysis and inhibited leptin, despite a significant increase in insulin. The response was rapidly reversed at the end of infusion, implicating the SNS (177). In trained rats exposed to exhaustive exercise, circulating leptin did not change but leptin mRNA expression was inhibited because of β 3-adrenergic receptor activation (29), demonstrating a dissociation between leptin expression and circulating leptin. Leptin was decreased in marathon or ultramarathon runners (131, 133), but this may have been secondary to loss of fat. Exhaustive exercise had no immediate effect on leptin in trained individuals (100), and exercise training did not change leptin once body fat had been taken into account (101, 176), but 2 h after an exercise bout, glycerol and FFA were increased and leptin was decreased (72). The dissociation between leptin expression and circulating leptin may result from inhibition of leptin clearance. Alternatively, as exercise activates the SNS and β -adrenergic agonists inhibit leptin expression while promoting lipolysis in adipocytes (151), it is possible that leptin secretion is actively stimulated during exercise. Following exercise, the decline in leptin would reflect the inhibition of leptin expression.

Leptin and the Hypothalamic-Pituitary-Thyroid Axis

Thyroid hormone concentrations also decrease in response to food restriction. The hypothalamic-pituitary-thyroid (HPT) axis regulates circulating concentrations of thyroid hormones and binding proteins. The hypothalamus produces

thyroid releasing hormone (TRH) that regulates secretion of thyroid stimulating hormone (TSH) from the pituitary gland. Thyroid hormones stimulate basal metabolic rate and increase heat production, in part, through regulation of mitochondrial UCPs (87, 202). Starvation is associated with low concentrations of hypothalamic pro TRH, low or normal TSH in the pituitary, and low-circulating triiodothyronine (T3) and thyroxine (T4). The relationship between leptin and the HPT axis was first observed when leptin blunted the reduction in thyroid hormones in fasted mice (2). In a second study, with rats repeatedly treated with leptin during a 3-day fast, weight loss was not prevented, but total and free T4 and T3 and hypothalamic pro-TRH mRNA levels were maintained (135). Leptin receptor mRNA is expressed in arcuate nucleus NPY containing neurons that synapse on TRH neurons in the paraventricular nucleus of the hypothalamus (91), therefore it was hypothesized that maintenance of pro-TRH was mediated by NPY (135). This is supported by observations that rats with arcuate nucleus damage had low T4, TSH, and leptin, but high corticosterone, compared with fed, control animals. Fasting these animals did not change pro-TRH, and leptin had no effect on the thyroid axis (136). In nonstress conditions, leptin may provide tonic regulation of thyroid hormones. The small number of humans with genetic leptin deficiency or insensitivity have normal concentrations of thyroid hormones but elevated TSH, indicating abnormal hypothalamic regulation of the thyroid axis (49). In obese subjects, the TSH response to TRH is increased (70), and there is a positive correlation between body fat content and TSH levels (178).

Evidence that thyroid hormones influence leptin is weak. Leptin expression and secretion in adipocytes from hypothyroid and euthyroid rats were not different (77), although T3 and T4 inhibited leptin expression and serum leptin concentrations in hypothyroid rats (78). In humans, there were no changes in leptin after a week of T3 treatment that increased heart rate and inhibited TSH (152). Evaluation of leptin status in hypo- and hyperthyroid patients showed no change in hyperthyroid patients but significant increases in the hypothyroid patients (137). There was no relationship between leptin and thyroid status when leptin was corrected to BMI (58), but BMI underestimates body fat in hyperthyroid subjects who have low concentrations of leptin relative to body fat mass (178). As thyroid hormones potentiate the effects of sympathetic activation, the inverse relationship between leptin and thyroid status may be secondary to increased catecholamine sensitivity.

LEPTIN AND REPRODUCTIVE FUNCTION

Leptin and the Hypothalamic-Pituitary Gonadal Axis

There is an optimal range of adiposity for fertility (83), and malnutrition—including starvation, obesity, and type I diabetes—disrupts reproduction at the hypothalamic/pituitary level. Leptin provides a link between fat and the hypothalamic-gonadal axis. Leptin mutation in humans causes obesity and hypogonadism (205),

and ob/ob and db/db mice are infertile because of hypothalamic-pituitary dysfunction (206), but leptin restored fertility in ob/ob mice (9, 40, 161). The effect on sexual maturation may be effected at both the hypothalamus and the gonads. Centrally, receptors do not colocalize with gonadotrophic releasing hormone in the hypothalamus; therefore, leptin must act indirectly in the arcuate nucleus, either recruiting POMC derivatives (61) or inhibiting NPY-containing neurons (5). In vitro, leptin stimulated secretion of rat hypothalamic gonadotrophic-releasing hormone, and of pituitary gonadotropins, follicle-stimulating hormone, and luteinizing hormone (LH) (237), and in vivo, it prevented inhibition of LH pulses during fasting (82). In the periphery, leptin receptors are expressed at high levels in reproductive organs (47). In vitro, leptin augmented estradiol release from leutinized ovarian granulosa cells in basal conditions and in cells stimulated by follicle stimulating hormone and IGF-1, increasing activity of aromatase enzymes (120). There was no effect of leptin in the absence of LH (113), implying that any effect on ovarian cells requires a functional hypothalamic-pituitary axis.

There is also evidence that gonadal steroids influence leptin release and activity. Plasma leptin is higher in women than in men for any given percentage of body fat (190). In children and adults, leptin is negatively associated with testosterone in males and positively correlated with estrogen in females, after accounting for fat mass (67, 226). In women, leptin fluctuations during the menstrual cycle correlate with estrogen, but they have no relationship with progesterone (149, 180). However, the gender difference is not a simple effect of estrogen, as leptin is the same in pre- and postmenopausal women and does not change with hormone replacement therapy (38). The gender difference is replicated in vitro. Leptin release is greater in fat from females than from males (37), and fat from females who still have ovaries is more responsive to dexamethasone and estradiol (37, 128), but in women who have undergone ovariectomies, the difference is abolished (128). In contrast, testosterone has been reported to inhibit (226), or to have no effect (128) on, leptin release. Estrogen can also influence leptin activity at the receptor level. In rats, all hypothalamic cells immunoreactive for estrogen receptors also expressed leptin receptors (69), and estrogen treatment of intact female rats down-regulated Ob-Ra receptors in all brain areas, but Ob-Rb was inhibited only in the hypothalamus. Ovariectomy did not change Ob-Rb but it increased Ob-Ra receptor expression (15). Although circulating leptin did not change during the estrous cycle, regulation of the receptor was not limited to pharmacological conditions because arcuate nucleus Ob-Rb expression was highest during estrous and metestrous and was inversely correlated with NPY expression (16), providing a potential mechanism for cyclic variations in energy intake and activity.

Leptin as a Signal for Sexual Maturation

The link between adiposity, leptin, and puberty is demonstrated by early puberty of obese children (121). In nonobese children, leptin triples during puberty in

females, whereas in males there is a prepubertal surge in leptin, which declines at the onset of puberty (150). At the end of puberty, leptin correlates negatively with LH and follicle-stimulating hormone in girls but there is no relationship with gonadotropins in boys (28). In adult males, testosterone and leptin are inversely correlated (222) and suppression of testosterone strengthens the relationship between body fat and leptin, which has been interpreted as inhibition of leptin by testosterone (222). In contrast, in androgenic women with polycystic ovary syndrome, there was no relationship between leptin and testosterone (224), which suggests a gender difference in hormone sensitivity.

Animal studies provided strong evidence that leptin is essential for sexual maturation. Leptin treatment accelerated onset of puberty and behavioral estrous in lean mice (41), although attempts to replicate these findings have not always been successful (61). In starved mice, leptin prevented a drop in LH, a delay in estrous or a fall in testosterone, and blunted hypothalamic NPY expression (2). In fed rats, leptin inhibited weight gain but prevented the delay in puberty that was apparent in pair-fed animals. In fasted rats, the delay was only partially reversed (88), and leptin treatment did not increase sexual behavior in fasted hamsters (228). Therefore, other metabolic factors, in addition to leptin, signal that body energy stores are adequate to support reproduction.

Leptin During Pregnancy

Although leptin is essential for fertility, it is not essential for maintaining pregnancy. In pregnant ob/ob mice treated with leptin prior to pregnancy, withdrawal of leptin did not prevent completion of the pregnancy (162). Placental leptin expression is similar to that in adipose tissue (138), and receptors are present in the placenta (118), although their function has not been determined. In humans, leptin is detected in cord blood at 18 weeks and increases dramatically at 34 weeks of gestation (108). It is not clear whether placental leptin enters the maternal circulation, as placental leptin expression and umbilical leptin were increased in mothers with insulin-dependent diabetes who were treated with insulin, but maternal leptin did not change (138). During pregnancy, maternal leptin is elevated before body composition changes (93, 102) and increases with gestation (98), which suggests the development of "leptin resistance." There is no correlation between maternal leptin and fetal birth weight (194), and post partum, leptin falls below baseline levels (93) possibly because of the energy cost of lactation.

It has been reported that cord blood leptin is higher for female than for male fetuses (108), indicating gender differences at a very early stage of development; however, others have not confirmed these observations (197). Cord leptin concentration correlates with birth weight (197) and with measures of fetal growth rather than with adiposity (221). This may be explained by *in vitro* observations that leptin stimulation of fetal pituitary tissue promoted release of GH but not ACTH, prolactin, or gonadotropins (199). Fetal leptin drops precipitously within hours of birth (108), implying that its function *in utero* changes at parturition.

CONCLUSIONS

There is substantial evidence that leptin activates, or modulates, a number of physiological systems independent of any effect on food intake. Many of the responses to leptin have been investigated in isolation, but multiple effects are mediated by the hypothalamus and pituitary gland; therefore, it is essential to confirm in vitro observations with in vivo studies in which simultaneous activation of divergent pathways may act synergistically or antagonistically. It has been demonstrated that obesity is associated with central "leptin resistance"; however, it is not yet clear whether in peripheral tissues resistance also develops secondarily to regulation of receptor expression or increased expression of binding proteins, which could reduce leptin bioavailability. Many observations described above were obtained from animals treated with exogenous leptin, and the responses in these animals did not always correspond with the outcome of increased endogenous leptin caused by weight gain. Therefore, future studies need to clarify the physiologic, versus pharmacologic, relevance of specific leptin activities. This research will determine whether leptin's primary function is as a satiety signal or whether it has more significant peripheral activities independent of food intake.

Visit the Annual Reviews home page at www.AnnualReviews.org

LITERATURE CITED

1. Ahima RS, Bjorbaek C, Osei S, Flier JS. 1999. Regulation of neuronal and glial proteins by leptin: implications for brain development. *Endocrinology* 140:2755–62
2. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, et al. 1996. Role of leptin in the neuroendocrine response to fasting. *Nature* 382:250–52
3. Ahren B, Larsson H. 1997. Leptin—a regulator of islet function? Its plasma levels correlate with glucagon and insulin secretion in healthy women. *Metabolism* 46:1477–81
4. Attia N, Caprio S, Jones TW, Heptulla R, Holcombe J, et al. 1999. Changes in free insulin-like growth factor-1 and leptin concentrations during acute metabolic decompensation in insulin withdrawn patients with type 1 diabetes. *J. Clin. Endocrinol. Metab.* 84:2324–28
5. Aubert ML, Pierroz DD, Gruaz NM, d'Alleva V, Vuagnat BA, et al. 1998. Metabolic control of sexual function and growth: role of neuropeptide Y and leptin. *Mol. Cell. Endocrinol.* 140:107–13
6. Bado A, Levasseur S, Attoub S, Kermorgant S, Laigneau JP, et al. 1998. The stomach is a source of leptin. *Nature* 394:790–93
7. Bai Y, Zhang S, Kim KS, Lee JK, Kim KH. 1996. Obese gene expression alters the ability of 30A5 preadipocytes to respond to lipogenic hormones. *J. Biol. Chem.* 271:13939–42
8. Deleted in proof
9. Barash IA, Cheung CC, Weigle DS, Ren H, Kabigting EB, et al. 1996. Leptin is a metabolic signal to the reproductive system. *Endocrinology* 137:3144–47
10. Barr VA, Malide D, Zarnowski MJ, Taylor SI, Cushman SW. 1997. Insulin stimulates both leptin secretion and production by rat white adipose tissue. *Endocrinology* 138:4463–72

11. Barzilai N, She L, Liu L, Wang J, Hu M, et al. 1999. Decreased visceral adiposity accounts for leptin effect on hepatic but not peripheral insulin action. *Am. J. Physiol.* 277:E291–98
12. Barzilai N, Wang J, Massilon D, Vuguin P, Hawkins M, Rossetti L. 1997. Leptin selectively decreases visceral adiposity and enhances insulin action. *J. Clin. Invest.* 100:3105–10
13. Baumann H, Morella KK, White DW, Dembski M, Bailon PS, et al. 1996. The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. *Proc. Natl. Acad. Sci. USA* 93:8374–78
14. Bennett BD, Solar GP, Yuan JQ, Mathias J, Thomas GR, Matthews W. 1996. A role for leptin and its cognate receptor in hematopoiesis. *Curr. Biol.* 6:1170–80
15. Bennett PA, Lindell K, Karlsson C, Robinson IC, Carlsson LM, Carlsson B. 1998. Differential expression and regulation of leptin receptor isoforms in the rat brain: effects of fasting and oestrogen. *Neuroendocrinology* 67:29–36
16. Bennett PA, Lindell K, Wilson C, Carlsson LM, Carlsson B, Robinson IC. 1999. Cyclical variations in the abundance of leptin receptors, but not in circulating leptin correlate with NPY expression during the oestrous cycle. *Neuroendocrinology* 69:417–23
17. Berti L, Kellerer M, Capp E, Haring HU. 1997. Leptin stimulates glucose transport and glycogen synthesis in C2C12 myotubes: evidence for a P13-kinase mediated effect. *Diabetologia* 40:606–9
18. Bjorbaek C, Elmquist JK, Frantz JD, Shoelson SE, Flier JS. 1998. Identification of SOCS-3 as a potential mediator of central leptin resistance. *Mol. Cell* 1:619–25
19. Boado RJ, Golden PL, Levin N, Pardridge WM. 1998. Up-regulation of blood-brain barrier short-form leptin receptor gene products in rats fed a high fat diet. *J. Neurochem.* 71:1761–64
20. Boden G, Chen X, Kolaczynski JW, Polansky M. 1997. Effects of prolonged hyperinsulinemia on serum leptin in normal human subjects. *J. Clin. Invest.* 100:1107–13
21. Boden G, Chen X, Mozzoli M, Ryan I. 1996. Effect of fasting on serum leptin in normal human subjects. *J. Clin. Endocrinol. Metab.* 81:3419–23
22. Boni-Schnetzler M, Gosteli-Peter MA, Moritz W, Froesch ER, Zapf J. 1996. Reduced ob mRNA in hypophysectomised rats is not restored by growth hormone (GH) but further suppressed by exogenously administered insulin-like growth factor (IGF) I. *Biochem. Biophys. Res. Commun.* 225:296–301
23. Boni-Schnetzler M, Hauri C, Zapf J. 1999. Leptin is suppressed during infusion of recombinant human insulin-like growth factor I (rhIGF I) in normal rats. *Diabetologia* 42:160–66
24. Bornstein SR. 1997. Is leptin a stress related peptide? *Nat. Med.* 3:937
25. Bornstein SR, Licinio J, Tauchnitz R, Engelmann L, Negrao AB, et al. 1998. Plasma leptin levels are increased in survivors of acute sepsis: associated loss of diurnal rhythm, in cortisol and leptin secretion. *J. Clin. Endocrinol. Metab.* 83:280–83
26. Bornstein SR, Uhlmann K, Haidan A, Ehrhart-Bornstein M, Scherbaum WA. 1997. Evidence for a novel peripheral action of leptin as a metabolic signal to the adrenal gland: Leptin inhibits cortisol release directly. *Diabetes* 46:1235–38
27. Bornstein SR, Vaudry H. 1998. Paracrine and neuroendocrine regulation of the adrenal gland—asic and clinical aspects. *Horm. Metab. Res.* 30:292–96
28. Bouvattier C, Lahlou N, Roger M, Bougneres P. 1998. Hyperleptinaemia is associated with impaired gonadotrophin response to GnRH during late puberty in obese girls, not boys. *Eur. J. Endocrinol.* 138:653–58
29. Bramlett SB, Zhou J, Harris RBS, Hendry SL, Witt TL, Zachweija JJ. 1999. Does

- β -adrenoreceptor blockade attenuate acute exercise induced reductions in leptin mRNA? *J. Appl. Physiol.* 87:1678–83
30. Bryson JM, Phuyal JL, Swan V, Caterson ID. 1999. Leptin has acute effects on glucose and lipid metabolism in both lean and gold thioglucose-obese mice. *Am. J. Physiol.* 277:E417–22
 31. Burcelin R, Kamohara S, Li J, Tannenbaum GS, Charron MJ, Friedman JM. 1999. Acute intravenous leptin infusion increases glucose turnover but not skeletal muscle glucose uptake in ob/ob mice. *Diabetes* 48:1264–69
 32. Cai A, Hyde JF. 1998. Upregulation of leptin receptor gene expression in the anterior pituitary of human growth hormone-releasing hormone transgenic mice. *Endocrinology* 139:420–23
 33. Cao GY, Considine RV, Lynn RB. 1997. Leptin receptors in the adrenal medulla of the rat. *Am. J. Physiol.* 273:E448–52
 34. Carlson GL, Saeed M, Little RA, Irving MH. 1999. Serum leptin concentrations and their relation to metabolic abnormalities in human sepsis. *Am. J. Physiol.* 276:E658–62
 35. Caro JF, Kolaczynski JW, Nyce MR, Ohanesian JP, Opentanova I, et al. 1996. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. *Lancet* 348:159–61
 36. Carro E, Senaris R, Considine RV, Casanueva FF, Dieguez C. 1997. Regulation of in vivo growth hormone secretion by leptin. *Endocrinology* 138:2203–6
 37. Casabiell X, Pineiro V, Peino R, Lage M, Camina J, et al. 1998. Gender differences in both spontaneous and stimulated leptin secretion by human omental adipose tissue in vitro: dexamethasone and estradiol stimulate leptin release in women, but not in men. *J. Clin. Endocrinol. Metab.* 83:2149–55
 38. Castracane VD, Kraemer RR, Franken MA, Kraemer GR, Gimpel T. 1998. Serum leptin concentration in women: effect of age, obesity, and estrogen administration. *Fertil. Steril.* 70:472–77
 39. Chandra RK, Au B. 1980. Spleen hemolytic plaque-forming cell response and generation of cytotoxic cells in genetically obese (C57Bl/6J ob/ob) mice. *Int. Arch. Allergy Appl. Immunol.* 62:94–98
 40. Chehab FF, Lim ME, Lu R. 1996. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. *Nat. Genet.* 12:318–20
 41. Chehab FF, Mounzih K, Lu R, Lim ME. 1997. Early onset of reproductive function in normal female mice treated with leptin. *Science* 275:88–90
 42. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, et al. 1996. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice *Cell* 84:491–95
 43. Chen NG, Romsos DR. 1997. Persistently enhanced sensitivity of pancreatic islets from ob/ob mice to PKC-stimulated insulin secretion. *Am. J. Physiol.* 272:E304–11
 44. Chen NG, Swick AG, Romsos DR. 1997. Leptin constrains acetylcholine-induced insulin secretion from pancreatic islets of ob/ob mice. *J. Clin. Invest.* 100:1174–79
 45. Chen NG, Tassava TM, Romsos DR. 1993. Threshold for glucose-stimulated insulin secretion in pancreatic islets of genetically obese (ob/ob) mice is abnormally low. *J. Nutr.* 123:1567–74
 46. Chinooskong N, Wang JL, Shi ZQ. 1999. Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat. *Diabetes* 48:1487–92
 47. Cioffi JA, Shafer AW, Zupancic TJ, Smith-Gbur J, Mikhail A, et al. 1996. Novel B219/OB receptor isoforms: possible role of leptin in hematopoiesis and reproduction. *Nat. Med.* 2:585–89
 48. Clement K, Lahlou N, Ruiz J, Hager J, Bougneres P, et al. 1997. Association of

- poorly controlled diabetes with low serum leptin in morbid obesity. *Int. J. Obes.* 21:556–61
49. Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, et al. 1998. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. *Nature* 392:398–401
50. Cocchi D, De Gennaro Colonna V, Bagnasco M, Bonacci D, Muller EE. 1999. Leptin regulates GH secretion in the rat by acting on GHRH and somatostatinergic functions. *J. Endocrinol.* 162:95–99
51. Cohen B, Novick D, Rubinstein M. 1996. Modulation of insulin activities by leptin. *Science* 274:1185–88
52. Cohen SM, Werrmann JG, Tota MR. 1998. ^{13}C NMR study of the effects of leptin treatment on kinetics of hepatic intermediary metabolism. *Proc. Natl. Acad. Sci. USA* 95:7385–90
53. Coleman DL. 1973. Effects of parabiosis of obese with diabetes and normal mice. *Diabetologia* 9:294–98
54. Coleman DL, Hummel KP. 1969. Effects of parabiosis of normal with genetically diabetic mice. *Am. J. Physiol.* 217:1298–304
55. Collins S, Cuhn CM, Petro AE, Swick AG, Chrunyk BA, Surwit RS. 1996. Role of leptin in fat regulation. *Nature*, 380:677
56. Considine RV, Nyce MR, Kolaczynski JW, Zhang PL, Ohannesian JP, et al. 1997. Dexamethasone stimulates leptin release from human adipocytes: unexpected inhibition by insulin. *J. Cell. Biochem.* 65:254–58
57. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, et al. 1996. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. *N. Engl. J. Med.* 334:292–95
58. Corbetta S, Englaro P, Giambona S, Persani L, Blum WF, Beck-Peccoz P. 1997. Lack of effects of circulating thyroid hormone levels on serum leptin concentrations. *Eur. J. Endocrinol.* 137:659–63
59. Cortez-Pinto H, Yang SQ, Lin HZ, Costa S, Hwang CS, et al. 1998. Bacterial lipopolysaccharide induces uncoupling protein-2 expression in hepatocytes by a tumor necrosis factor- α -dependent mechanism. *Biochem. Biophys. Res. Commun.* 251:313–19
60. Coutant R, Lahlou N, Bouvattier C, Bougneres P. 1998. Circulating leptin level and growth hormone response to stimulation tests in obese and normal children. *Eur. J. Endocrinol.* 139:591–97
61. Cunningham MJ, Clifton DK, Steiner RA. 1999. Leptin's actions on the reproductive axis: perspectives and mechanisms. *Biol. Reprod.* 60:216–22
62. Cusin I, Sainsbury A, Doyle P, Rohner-Jeanrenaud F, Jeanrenaud B. 1995. The obese gene and insulin. A relationship leading to clues to the understanding of obesity. *Diabetes* 44:1467–70
63. Cusin I, Zakrzewska KE, Boss O, Muzzin P, Giacobino JP, et al. 1998. Chronic central leptin infusion enhances insulin-stimulated glucose metabolism and favors the expression of uncoupling proteins. *Diabetes* 47:1014–19
64. D'Adamo M, Buongiorno A, Maroccia E, Leonetti F, Barbetti F, et al. 1998. Increased OB gene expression leads to elevated plasma leptin concentrations in patients with chronic primary hyperinsulinemia. *Diabetes* 47:1625–29
65. Dagogo-Jack S, Fanelli C, Paramore D, Brothers J, Landt M. 1996. Plasma leptin and insulin relationships in obese and nonobese humans. *Diabetes* 45:695–98
66. Dagogo-Jack S, Selke G, Melson AK, Newcomer AW. 1997. Robust leptin secretory responses to dexamethasone in obese subjects. *J. Clin. Endocrinol. Metab.* 82:3230–33
67. Demerath EW, Towne B, Wisemandle W, Blangero J, Chumlea WC, Siervogel RM. 1999. Serum leptin concentration, body composition, and gonadal hormones during puberty. *Int. J. Obes.* 23:678–85

68. De Vos P, Saladin R, Auwerx J, Staels B. 1995. Induction of ob gene expression by corticosteroids is accompanied by body weight loss and reduced food intake. *J. Biol. Chem.* 270:15958–61
69. Diano S, Kalra SP, Sakamoto H, Horvath TL. 1998. Leptin receptors in estrogen receptor-containing neurons of the female rat hypothalamus. *Brain Res.* 812:256–59
70. Donders SH, Pieters GF, Heevel JG, Ross HA, Smals AG, Kloppenborg PW. 1985. Disparity of thyrotropin (TSH) and prolactin responses to TSH-releasing hormone in obesity. *J. Clin. Endocrinol. Metab.* 61:56–59
71. Dubuc GR, Phinney SD, Stern JS, Havel PJ. 1998. Changes of serum leptin and endocrine and metabolic parameters after 7 days of energy restriction in men and women. *Metabolism* 47:429–34
72. Duclos M, Corcuff JB, Ruffie A, Roger P, Manier G. 1999. Rapid leptin decrease in immediate post-exercise recovery. *Clin. Endocrinol.* 50:337–42
73. Elimam A, Knutsson U, Bronnegard M, Stierna P, Albertsson-Wikland K, Marcus C. 1998. Variations in glucocorticoid levels within the physiological range affect plasma leptin levels. *Eur. J. Endocrinol.* 139:615–20
74. Emilsson V, Liu YL, Cawthorne MA, Morton NM, Davenport M. 1997. Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. *Diabetes* 46:313–16
75. Faggioni R, Fantuzzi G, Fuller J, Dinarello CA, Feingold KR, Grunfeld C. 1998. IL-1 beta mediates leptin induction during inflammation. *Am. J. Physiol.* 274:R204–8
76. Faggioni R, Fuller J, Moser A, Feingold KR, Grunfeld C. 1997. LPS-induced anorexia leptin-deficient (ob/ob) and leptin receptor-deficient (db/db) mice. *Am. J. Physiol.* 273:R181–86
77. Fain JN, Bahouth SW. 1998. Hormonal regulation of 18S RNA, leptin mRNA and leptin release in adipocytes from hypothalamic rats. *Metabolism* 47:1455–61
78. Fain JN, Coronel EC, Beauchamp MJ, Bahouth SW. 1997. Expression of leptin and beta 3-adrenergic receptors in rat adipose tissue in altered thyroid states. *Biochem. J.* 322:145–50
79. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, et al. 1999. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. *N. Engl. J. Med.* 341:879–84
80. Fernandes G, Handwerger BS, Yunis EJ, Brown DM. 1978. Immune response in the mutant diabetic C57BL/Ks-dt+ mouse. Discrepancies between in vitro and in vivo immunological assays. *J. Clin. Invest.* 61:243–50
81. Finck BN, Kelley KW, Dantzer R, Johnson RW. 1998. In vivo and in vitro evidence for the involvement of tumor necrosis factor-alpha in the induction of leptin by lipopolysaccharide. *Endocrinology* 139:2278–83
82. Finn PD, Cunningham MJ, Pau KY, Spies HG, Clifton DK, Steiner RA. 1998. The stimulatory effect of leptin on the neuroendocrine reproductive axis of the monkey. *Endocrinology* 139:4652–62
83. Frisch RE. 1987. Body fat, menarche, fitness and fertility. *Hum. Reprod.* 2:521–33
84. Fruhbeck G, Aguado M, Martinez JA. 1997. In vitro lipolytic effect of leptin on mouse adipocytes: evidence for a possible autocrine/paracrine role of leptin. *Biochem. Biophys. Res. Commun.* 240:590–94
85. Gainsford T, Willson TA, Metcalf D, Handman E, McFarlane C, et al. 1996. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. *Proc. Natl. Acad. Sci. USA* 93:14564–68
86. Glasow A, Haidan A, Hilbers U, Breidert M, Gillespie J, et al. 1998. Expression of Ob receptor in normal human adrenals: differential regulation of adrenocortical

- and adrenomedullary function by leptin. *J. Clin. Endocrinol. Metab.* 83:4459–66
87. Gong DW, He Y, Karas M, Reitman M. 1997. Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone, β_3 -adrenergic agonists, and leptin. *J. Biol. Chem.* 272:24129–32
88. Gruaz NM, Lalaoui M, Pierroz DD, Englaro P, Sizonenko PC, et al. 1998. Chronic administration of leptin into the lateral ventricle induces sexual maturation in severely food-restricted female rats. *J. Neuroendocrinol.* 10:627–33
89. Grunfeld C, Zhao C, Fuller J, Pollack A, Moser A, et al. 1996. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. *J. Clin. Invest.* 97:2152–57
90. Haffner SM, Miettinen H, Mykkanen L, Stern MP. 1998. Leptin concentrations are associated with higher proinsulin and insulin concentrations but a lower proinsulin/insulin ratio in non-diabetic subjects. *Int. J. Obes.* 22:899–905
91. Hakansson ML, Brown H, Ghilardi N, Skoda RC, Meister B. 1998. Leptin receptor immunoreactivity in chemically defined target neurons of the hypothalamus. *J. Neurosci.* 18:559–72
92. Halleux CM, Servais I, Reul BA, Detry R, Brichard SM. 1998. Multihormonal control of ob gene expression and leptin secretion from cultured human visceral adipose tissue: increased responsiveness to glucocorticoids in obesity. *J. Clin. Endocrinol. Metab.* 83:902–10
93. Hardie L, Trayhurn P, Abramovich D, Fowler P. 1997. Circulating leptin in women: a longitudinal study in the menstrual cycle and during pregnancy. *Clin. Endocrinol.* 47:101–6
94. Harris RBS. 1998. Acute and chronic effects of leptin on glucose utilization in lean mice. *Biochem. Biophys. Res. Commun.* 245:502–9
95. Harris RBS, Zhou J, Redmann SM Jr, Smagin GN, Smith SR, et al. 1998. A leptin dose-response study in obese (ob/ob) and lean (+/?) mice. *Endocrinology* 139:8–19
96. Harvey J, Ashford ML. 1998. Insulin occludes leptin activation of ATP-sensitive K^+ channels in rat CRI-G1 insulin secreting cells. *J. Physiol.* 511:695–706
97. Heiman ML, Ahima RS, Craft LS, Schoner B, Stephens TW, Flier JS. 1997. Leptin inhibition of the hypothalamic-pituitary-adrenal axis in response to stress. *Endocrinology* 138:3859–63
98. Henson MC, Swan KF, O'Neil JS. 1998. Expression of placental leptin and leptin receptor transcripts in early pregnancy and at term. *Obstet. Gynecol.* 92:1020–28
99. Hervey GR. 1959. The effects of lesions in the hypothalamus in parabiotic rats. *J. Physiol.* 145:336–52
100. Hickey MS, Considine RV, Israel RG, Mahar TL, McCammon MR, et al. 1996. Leptin is related to body fat content in male distance runners. *Am. J. Physiol.* 271:E938–40
101. Hickey MS, Houmard JA, Considine RV, Tyndall GL, Midgette JB, et al. 1997. Gender-dependent effects of exercise training on serum leptin levels in humans. *Am. J. Physiol.* 272:E562–66
102. Highman TJ, Friedman JE, Huston LP, Wong WW, Catalano PM. 1998. Longitudinal changes in maternal serum leptin concentrations, body composition and resting metabolic rate in pregnancy. *Am. J. Obstet. Gynecol.* 178:1010–15
103. Huang Q, Rivest R, Richard D. 1998. Effects of leptin on corticotropin-releasing factor (CRF) synthesis and CRF neuron activation in the paraventricular hypothalamic nucleus of obese (ob/ob) mice. *Endocrinology* 139:1524–32
104. Islam MS, Morton NM, Hansson M, Emilsson V. 1997. Rat insulinoma-derived pancreatic beta-cells express a functional leptin receptor that mediates a proliferative response. *Biochem. Biophys. Res. Commun.* 238:851–55

105. Iozaki O, Tsushima T, Miyakawa M, Nozoe Y, Demura H, Seki H. 1999. Growth hormone directly inhibits leptin gene expression in visceral fat tissue in fatty Zucker rats. *J. Endocrinol.* 161:511–16
106. Iozaki O, Tsushima T, Nozoe Y, Demura H, Seki H. 1998. Effects of growth hormone on leptin gene expression in rats. *Endocr. J.* 45(Suppl.):S117–19
107. Janik JE, Curti BD, Considine RV, Rager HC, Powers GC, et al. 1997. Interleukin 1 alpha increases serum leptin concentrations in humans. *J. Clin. Endocrinol. Metab.* 82:3084–86
108. Jaquet D, Leger J, Levy-Marchal C, Oury JF, Czernichow P. 1998. Ontogeny of leptin in human fetuses and newborns: effect of intrauterine growth retardation on serum leptin concentrations. *J. Clin. Endocrinol. Metab.* 83:1243–46
109. Jin L, Burguera BG, Couce ME, Scheithauer BW, Lamsan J, et al. 1999. Leptin and leptin receptor expression in normal and neoplastic human pituitary: evidence of a regulatory role for leptin on pituitary cell proliferation. *J. Clin. Endocrinol. Metab.* 84:2903–11
110. Johannsson G, Karlsson C, Lonn L, Marin P, Bjorntorp P, et al. 1998. Serum leptin concentration and insulin sensitivity in men with abdominal obesity. *Obes. Res.* 6:416–21
111. Kamoda T, Saitoh H, Nakahara S, Izumi I, Hirano T, Matsui A. 1998. Serum leptin and insulin concentrations in prepubertal lean, obese and insulin-dependent diabetes mellitus children. *Clin. Endocrinol.* 49:385–89
112. Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ. 1997. Acute stimulation of glucose metabolism in mice by leptin treatment. *Nature* 389:374–77
113. Karlsson C, Lindell K, Svensson E, Bergh C, Lind P, et al. 1997. Expression of functional leptin receptors in the human ovary. *J. Clin. Endocrinol. Metab.* 82:4144–48
114. Karlsson C, Stenlof K, Johannsson G, Marin P, Bjorntorp P, et al. 1998. Effects of growth hormone treatment on the leptin system and on energy expenditure in abdominally obese men. *Eur. J. Endocrinol.* 138:408–14
115. Kellerer M, Koch M, Metzinger E, Mushack J, Capp E, Haring HU. 1997. Leptin activates PI-3 kinase in C2C12 myotubes via janus kinase-2 (JAK-2) and insulin receptor substrate-2 (IRS-2) dependent pathways. *Diabetologia* 40:1358–62
116. Kennedy GC. 1953. The role of depot fat in the hypothalamic control of food intake in rats. *Proc. R. Soc. London Ser. B* 140:578–92
117. Kieffer TJ, Heller RS, Leech CA, Holz GG, Habener JF. 1997. Leptin suppression of insulin secretion by the activation of ATP-sensitive K⁺ channels in pancreatic β -cells. *Diabetes* 46:1087–93
118. Kielar D, Clark JS, Ciechanowicz A, Kurzawski G, Sulikowski T, Naruszewicz M. 1998. Leptin receptor isoforms expressed in human adipose tissue. *Metabolism* 47:844–47
119. Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. 1997. Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. *J. Clin. Invest.* 100:2777–82
120. Kitawaki J, Kusuki I, Koshiha H, Tsukamoto K, Honjo H. 1999. Leptin directly stimulates aromatase activity in human luteinized granulosa cells. *Mol. Hum. Reprod.* 5:708–13
121. Klein KO, Larmore KA, de Lancy E, Brown JM, Considine RV, Hassink SG. 1998. Effect of obesity on estradiol level, and its relationship to leptin, bone maturation, and bone mineral density in children. *J. Clin. Endocrinol. Metab.* 83:3469–75

122. Koistinen HA, Tuominen JA, Ebeling P, Heiman ML, Stephens TW, Koivisto VA. 1998. The effect of exercise on leptin concentration in healthy men and in type 1 diabetic patients. *Med. Sci. Sports Exerc.* 30:805–10
123. Kolaczynski JW, Considine RV, Ohanesian J, Marco C, Opentanova I, et al. 1996. Responses of leptin to short-term fasting and refeeding in humans: a link with ketogenesis but not ketones themselves. *Diabetes* 45:1511–15
124. Kolaczynski JW, Nyce MR, Considine RV, Boden G, Nolan JJ, et al. 1996. Acute and chronic effects of insulin on leptin production in humans: studies in vivo and in vitro. *Diabetes* 45:699–701
125. Konopleva M, Mikhail A, Estrov Z, Zhao S, Harris D, et al. 1999. Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. *Blood* 93:1668–76
126. Koopmans SJ, Frolich M, Gribnau EH, Westendorp RG, DeFronzo RA. 1998. Effect of hyperinsulinemia on plasma leptin concentrations and food intake in rats. *Am. J. Physiol.* 274:E998–1001
127. Koyama K, Chen G, Wang MY, Lee Y, Shimabukuro M, et al. 1997. β -Cell function in normal rats made chronically hyperleptinemic by adenovirus-leptin gene therapy. *Diabetes* 8:1276–80
- 127a. Kozak LP, Harper M-E. 2000. Uncoupling proteins in energy expenditure. *Annu. Rev. Nutr.* 20:339–63
128. Kristensen K, Pedersen SB, Richelsen B. 1999. Regulation of leptin by steroid hormones in rat adipose tissue. *Biochem. Biophys. Res. Commun.* 259:624–30
129. Kulkarni RN, Wang ZL, Wang RM, Hurlley JD, Smith DM, et al. 1997. Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice. *J. Clin. Invest.* 100:2729–36
130. Laharrague P, Larrouy D, Fontanilles AM, Truel N, Campfield A, et al. 1998. High expression of leptin by human bone marrow adipocytes in primary culture. *FASEB J.* 12:747–52
131. Landt M, Lawson GM, Helgeson JM, Davila-Roman VG, Ladenson JH, et al. 1997. Prolonged exercise decreases serum leptin concentrations. *Metabolism* 46:1109–12
132. Larsson H, Elmstahl S, Ahren B. 1996. Plasma leptin levels correlate to islet function independently of body fat in postmenopausal women. *Diabetes* 45:1580–84
133. Leal-Cerro A, Garcia-Luna PP, Astorga R, Parejo J, Peino R, et al. 1998. Serum leptin levels in male marathon athletes before and after the marathon run. *J. Clin. Endocrinol. Metab.* 83:2376–79
134. Leclercq-Meyer V, Considine RV, Sener A, Malaisse WJ. 1996. Do leptin receptors play a functional role in the endocrine pancreas? *Biochem. Biophys. Res. Commun.* 229:794–98
135. Legradi G, Emerson CH, Ahima RS, Flier JS, Lechan RM. 1997. Leptin prevents fasting-induced suppression of prothyrotropin-releasing hormone messenger ribonucleic acid in neurons of the hypothalamic paraventricular nucleus. *Endocrinology* 138:2569–76
136. Legradi G, Emerson CH, Ahima RS, Rand WM, Flier JS, Lechan RM. 1998. Arcuate nucleus ablation prevents fasting-induced suppression of ProTRH mRNA in the hypothalamic paraventricular nucleus. *Neuroendocrinology* 68:89–97
137. Leonhardt U, Ritzel U, Schafer G, Becker W, Ramadori G. 1998. Serum leptin levels in hypo- and hyperthyroidism. *J. Endocrinol.* 157:75–79
138. Lepercq J, Cauzac M, Lahlou N, Timsit J, Girard J, et al. 1998. Overexpression of placental leptin in diabetic pregnancy: a critical role for insulin. *Diabetes* 47:847–50

139. Leroy P, Dessolin S, Villageois P, Moon BC, Friedman JM, et al. 1996. Expression of ob gene in adipose cells. Regulation by insulin. *J. Biol. Chem.* 271:2365–68
140. Levin N, Nelson C, Gurney A, Vandlen R, de Sauvage F. 1996. Decreased food intake does not completely account for adiposity reduction after ob protein infusion. *Proc. Natl. Acad. Sci. USA* 93:1726–30
141. Licinio J, Mantzoros C, Negrao AB, Cizza G, Wong ML, et al. 1997. Human leptin levels are pulsatile and inversely related to pituitary adrenal function. *Nat. Med.* 3:575–79
142. Liu L, Karkanias GB, Morales JC, Hawkins M, Barzilai N, et al. 1998. Intracerebroventricular leptin regulates hepatic but not peripheral glucose fluxes. *J. Biol. Chem.* 273:31160–67
143. Liu YL, Emilsson V, Cawthorne MA. 1997. Leptin inhibits glycogen synthesis in the isolated soleus muscle of obese (ob/ob) mice. *FEBS Lett.* 411:351–55
144. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, et al. 1998. Leptin regulates proinflammatory immune responses. *FASEB J.* 12:57–65
145. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. 1998. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. *Nature* 394:897–901
146. MacDougald OA, Hwang CS, Fan H, Lane MD. 1995. Regulated expression of the obese gene product (leptin) in white adipose tissue and 3T3-L1 adipocytes. *Proc. Natl. Acad. Sci. USA* 92:9034–37
147. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, et al. 1995. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. *Nat. Med.* 1:1155–61
148. Malmstrom R, Taskinen MR, Karonen SL, Yki-Jarvinen H. 1996. Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM. *Diabetologia* 39:993–96
149. Mannucci E, Ognibene A, Becorpi A, Cremasco F, Pellegrini S, et al. 1998. Relationship between leptin and oestrogens in healthy women. *Eur. J. Endocrinol.* 139:198–201
150. Mantzoros CS, Flier JS, Rogol AD. 1997. A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. V. Rising leptin levels may signal the onset of puberty. *J. Clin. Endocrinol. Metab.* 82:1066–70
151. Mantzoros CS, Qu D, Frederich RC, Susulic VS, Lowell BB, et al. 1996. Activation of $\beta(3)$ adrenergic receptors suppresses leptin expression and mediates a leptin-independent inhibition of food intake in mice. *Diabetes* 45:909–14
152. Mantzoros CS, Rosen HN, Greenspan SL, Flier JS, Moses AC. 1997. Short-term hyperthyroidism has no effect on leptin levels in man. *J. Clin. Endocrinol. Metab.* 82:497–99
153. Marks JL, Waite K. 1997. Intracerebroventricular neuropeptide Y acutely influences glucose metabolism and insulin sensitivity in the rat. *J. Neuroendocrinol.* 9:99–103
154. Matkovic V, Ilich JZ, Skugor M, Badenhop NE, Goel P, et al. 1997. Leptin is inversely related to age at menarche in human females. *J. Clin. Endocrinol. Metab.* 82:3239–45
155. Mick G, Vanderbloomer T, Fu CL, McCormick K. 1998. Leptin does not affect adipocyte glucose metabolism: studies in fresh and cultured adipocytes. *Metabolism* 47:1360–65
156. Miell JP, Englaro P, Blum WF. 1996. Dexamethasone induces an acute and sustained rise in circulating leptin levels in normal human subjects. *Horm. Metab. Res.* 28:704–7
157. Mizuno TM, Bergen H, Funabashi T, Kleopoulos SP, Zhong YG, et al. 1996.

- Obese gene expression: reduction by fasting and stimulation by insulin and glucose in lean mice, and persistent elevation in acquired (diet-induced) and genetic (yellow agouti) obesity. *Proc. Natl. Acad. Sci. USA* 93:3434–38
158. Mizuno TM, Kleopoulos SP, Bergen HT, Roberts JL, Priest CA, Mobbs CV. 1998. Hypothalamic pro-opiomelanocortin mRNA is reduced by fasting and in ob/ob and db/db mice, but is stimulated by leptin. *Diabetes* 47:294–97
159. Morash P, Li A, Wilkinson M, Ur E. 1999. Leptin gene expression in rat brain. *Endocrine. Soc. Abstr.*, p. 418
160. Moshycdi AK, Josephs MD, Abdalla EK, Mackay SL, Edwards CK, et al. 1998. Increased leptin expression in mice with bacterial peritonitis is partially regulated by tumor necrosis factor alpha. *Infect. Immun.* 66:1800–2
161. Mounzih K, Lu R, Chehab FF. 1997. Leptin treatment rescues the sterility of genetically obese ob/ob males. *Endocrinology* 138:1190–93
162. Mounzih K, Qiu J, Ewart-Toland A, Chehab FF. 1998. Leptin is not necessary for gestation and parturition but regulates maternal nutrition via a leptin resistance state. *Endocrinology* 139:5259–62
163. Mueller WM, Gregoire FM, Stanhope KL, Mobbs CV, Mizuno TM, et al. 1998. Evidence that glucose metabolism regulates leptin secretion from cultured rat adipocytes. *Endocrinology* 139:551–58
164. Muller G, Ertl J, Gerl M, Preibisch G. 1997. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. *J. Biol. Chem.* 272:10585–93
165. Muoio DM, Dohn GL, Fiedorek FT, Tapscott EB, Coleman RA. 1997. Leptin directly alters lipid partitioning in skeletal muscle. *Diabetes* 48:1360–63
166. Nakashima K, Narazaki M, Taga T. 1997. Leptin receptor (OB-R) oligomerizes with itself but not with its closely related cytokine signal transducer gp130. *FEBS Lett.* 403:79–82
167. Nemezc M, Preininger K, Englisch R, Furnsinn C, Schneider B, et al. 1999. Acute effect of leptin on hepatic glycogenolysis and gluconeogenesis in perfused rat liver. *Hepatology* 29:166–72
168. Newcomer JW, Selke G, Melson AK, Gross J, Vogler GP, Dagogo-Jack S. 1998. Dose-dependent cortisol-induced increases in plasma leptin concentration in healthy humans. *Arch. Gen. Psychol.* 55:995–1000
169. Norrelund H, Gravholt CH, Englaro P, Blum WF, Rascher W, et al. 1998. Increased levels but preserved diurnal variation of serum leptin in GH-deficient patients: lack of impact of different modes of GH administration. *Eur. J. Endocrinol.* 138:644–52
170. O'Doherty RM, Anderson PR, Zhao AZ, Bornfeldt KE, Newgard CB. 1999. Sparing effect of leptin on liver glycogen stores in rats during the fed-to-fasted transition. *Am. J. Physiol.* 277:E544–50
171. Ookuma M, Ookuma K, York DA. 1998. Effects of leptin on insulin secretion from isolated rat pancreatic islets. *Diabetes* 47:219–23
172. Pallett AL, Morton NM, Cawthorne MA, Emilsson V. 1997. Leptin inhibits insulin secretion and reduces insulin mRNA levels in rat isolated pancreatic islets. *Biochem. Biophys. Res. Commun.* 38:267–70
173. Papaspyrou-Rao S, Schneider SH, Petersen RN, Fried SK. 1997. Dexamethasone increases leptin expression in humans in vivo. *J. Clin. Endocrinol. Metab.* 82:1635–37
174. Patel BK, Koenig JI, Kaplan LM, Hooi SC. 1998. Increase in plasma leptin and Lep mRNA concentrations by food intake is dependent on insulin. *Metabolism* 47:603–7
175. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, et al. 1995. Effects of the obese gene product on body

- weight regulation in ob/ob mice. *Science* 269:540–43
176. Perusse L, Collier G, Gagnon J, Leon AS, Rao DC, et al. 1997. Acute and chronic effects of exercise on leptin levels in humans. *J. Appl. Physiol.* 83:5–10
 177. Pinkney JH, Coppack SW, Mohamed-Ali V. 1998. Effect of isoprenaline on plasma leptin and lipolysis in humans. *Clin. Endocrinol.* 48:407–11
 178. Pinkney JH, Goodrick SJ, Katz J, Johnson AB, Lightman SL, et al. 1998. Leptin and the pituitary-thyroid axis: a comparative study in lean, obese, hypothyroid and hyperthyroid subjects. *Clin. Endocrinol.* 49:583–88
 179. Poitout V, Rouault C, Guerre-Millo M, Briaud I, Reach G. 1998. Inhibition of insulin secretion by leptin in normal rodent islets of Langerhans. *Endocrinology* 139:822–26
 180. Quinton ND, Laird SM, Okon MA, Li TC, Smith RF, et al. 1999. Serum leptin levels during the menstrual cycle of healthy fertile women. *Br. J. Biomed. Sci.* 56:16–19
 181. Raber J, Chen S, Mucke L, Feng L. 1997. Corticotropin-releasing factor and adrenocorticotrophic hormone as potential central mediators of OB effects. *J. Biol. Chem.* 272:15057–60
 182. Ramsay T. 1998. Leptin inhibits protein breakdown in muscle cells. *FASEB J.* 12:A865 (Abstr.)
 183. Ranganathan S, Ciaraldi TP, Henry RR, Mudaliar S, Kern PA. 1998. Lack of effect of leptin on glucose transport, lipoprotein lipase, and insulin action in adipose and muscle cells. *Endocrinology* 139:2509–13
 184. Rauch F, Blum WF, Klein K, Allolio B, Schonau E. 1998. Does leptin have an effect on bone in adult women? *Calcif. Tissue Int.* 63:453–55
 185. Rettori V, Milenkovic L, Aguila MC, McCann SM. 1990. Physiologically significant effect of neuropeptide Y to suppress growth hormone release by stimulating somatostatin discharge. *Endocrinology* 126:2296–301
 186. Rosario LM, Atwater I, Rojas E. 1985. Membrane potential measurements in islets of Langerhans from ob/ob obese mice suggest an alteration in $[Ca^{2+}]_i$ -activated K^+ permeability. *Q. J. Exp. Physiol.* 70:137–50
 187. Rossetti L, Massillon D, Barzilai N, Vuguin P, Chen W, et al. 1997. Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin action. *J. Biol. Chem.* 44:27758–63
 188. Russell CD, Petersen RN, Rao SP, Ricci MR, Prasad A, et al. 1998. Leptin expression in adipose tissue from obese humans: depot-specific regulation by insulin and dexamethasone. *Am. J. Physiol.* 275:E507–15
 189. Saad MF, Khan A, Sharma A, Michael R, Riad-Gabriel MG, et al. 1998. Physiological insulinemia acutely modulates plasma leptin. *Diabetes* 47:544–49
 190. Saad MF, Riad-Gabriel MG, Khan A, Sharma A, Michael R, et al. 1998. Diurnal and ultradian rhythmicity of plasma leptin: effects of gender and adiposity. *J. Clin. Endocrinol. Metab.* 83:453–59
 191. Saladin R, De Vos P, Guerre-Millo M, Leturque A, Girard J, et al. 1995. Transient increase in obese gene expression after food intake or insulin administration. *Nature* 377:527–29
 192. Scacchi M, Pincelli AI, Cavagnini F. 1999. Growth hormone in obesity. *Int. J. Obes.* 23:260–77
 193. Schoeller DA, Cella LK, Sinha MK, Caro JF. 1997. Entrainment of the diurnal rhythm of plasma leptin to meal timing. *J. Clin. Invest.* 100:1882–87
 194. Schubring C, Kiess W, Englaro P, Rascher W, Dotsch J, et al. 1997. Levels of leptin in maternal serum, amniotic fluid, and arterial and venous cord blood: relation to neonatal and placental weight. *J. Clin. Endocrinol. Metab.* 82:1480–83
 195. Schwartz MW, Baskin DG, Bukowski

- TR, Kuijper JL, Foster D, et al. 1996. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. *Diabetes* 45:531–35
196. Schwartz MW, Seeley RJ, Woods SC, Weigle DS, Campfield LA, et al. 1997. Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. *Diabetes* 46: 2119–23
197. Shekhawat PS, Garland JS, Shivpuri C, Mick GJ, Sasidharan P, et al. 1998. Neonatal cord blood leptin: its relationship to birth weight, body mass index, maternal diabetes, and steroids. *Pediatr. Res.* 43:338–43
198. Shimabukuro M, Koyama K, Chen G, Wang MY, Trieu F, et al. 1997. Direct anti-diabetic effect of leptin through triglyceride depletion of tissues. *Proc. Natl. Acad. Sci. USA* 94:4637–41
199. Shimon I, Yan X, Magoffin DA, Friedman TC, Melmed S. 1998. Intact leptin receptor is selectively expressed in human fetal pituitary and pituitary adenomas and signals human fetal pituitary growth hormone secretion. *J. Clin. Endocrinol. Metab.* 83:4059–64
200. Siegrist-Kaiser CA, Pauli V, Juge-Aubry CE, Boss O, Pernin A, et al. 1997. Direct effects of leptin on brown and white adipose tissue. *J. Clin. Invest.* 100:2858–64
201. Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, et al. 1998. Biological action of leptin as an angiogenic factor. *Science* 281:1683–86
202. Silva JE. 1995. Thyroid hormone control of thermogenesis and energy balance. *Thyroid* 5:481–92
203. Sindelar DK, Havel PJ, Seeley RJ, Wilkinson CW, Woods SC, Schwartz MW. 1999. Low plasma leptin levels contribute to diabetic hyperphagia in rats. *Diabetes* 48:1275–80
204. Slieker LJ, Sloop KW, Surface PL, Kriaciunas A, LaQuier F, et al. 1996. Regulation of expression of ob mRNA and protein by glucocorticoids and cAMP. *J. Biol. Chem.* 271:5301–4
205. Strobel A, Issat T, Camoin L, Ozata M, Strosberg AD. 1998. A leptin missense mutation associated with hypogonadism and morbid obesity. *Nat. Genet.* 18:213–15
206. Swerdloff RS, Batt RA, Bray GA. 1976. Reproductive hormonal function in the genetically obese (ob/ob) mouse. *Endocrinology* 98:1359–64
207. Takahashi N, Waelput W, Guisez Y. 1999. Leptin is an endogenous protective protein against the toxicity exerted by tumor necrosis factor. *J. Exp. Med.* 189:207–12
208. Takahashi Y, Okimura Y, Mizuno I, Iida K, Takahashi T, et al. 1997. Leptin induces mitogen-activated protein kinase-dependent proliferation of C3H10T1/2 cells. *J. Biol. Chem.* 272:12897–900
209. Takekoshi K, Motooka M, Isobe K, Nomura F, Manmoku T, et al. 1999. Leptin directly stimulates catecholamine secretion and synthesis in cultured porcine adrenal medullary chromaffin cells. *Biochem. Biophys. Res. Commun.* 261:426–31
210. Tan JT, Patel BK, Kaplan LM, Koenig JJ, Hooi SC. 1998. Regulation of leptin expression and secretion by corticosteroids and insulin. Implications for body weight. *Endocrine* 8:85–92
211. Tanabe K, Okuya S, Tanizawa Y, Matsutani A, Oka Y. 1997. Leptin induces proliferation of pancreatic beta cell line MIN6 through activation of mitogen-activated protein kinase. *Biochem. Biophys. Res. Commun.* 241:765–68
212. Tanizawa Y, Okuya S, Ishihara H, Asano T, Yada T, Oka Y. 1997. Direct stimulation of basal insulin secretion by physiological concentrations of leptin in pancreatic beta cells. *Endocrinology* 138:4513–16

213. Tannenbaum GS, Gurd W, Lapointe M. 1998. Leptin is a potent stimulator of spontaneous pulsatile growth hormone (GH) secretion and the GH response to GH-releasing hormone. *Endocrinology* 139:3871–75
214. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, et al. 1995. Identification and expression cloning of a leptin receptor, OB-R. *Cell* 83:1263–71
215. Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. 1999. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. *Endocrinology* 140:1630–38
216. Torpy DJ, Bornstein SR, Cizza G, Chrousos GP. 1998. The effects of glucocorticoids on leptin levels in humans may be restricted to acute pharmacologic dosing. *J. Clin. Endocrinol. Metab.* 83:1821–22
217. Utriainen T, Malmstrom R, Makimattila S, Yki-Jarvinen H. 1996. Supraphysiological hyperinsulinemia increases plasma leptin concentrations after 4 h in normal subjects. *Diabetes* 45:1364–66
218. Van den Berghe G, Wouters P, Carlsson L, Baxter RC, Bouillon R, Bowers CY. 1998. Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone. *J. Clin. Endocrinol. Metab.* 83:3062–70
219. van Dijk G, Donahey JC, Thiele TE, Scheurink AJ, Steffens AB, et al. 1997. Central leptin stimulates corticosterone secretion at the onset of the dark phase. *Diabetes* 46:1911–14
220. Van Harmelen V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, et al. 1998. Leptin secretion from subcutaneous and visceral adipose tissue in women. *Diabetes* 47:913–17
221. Varvarigou A, Mantzoros CS, Beratis NG. 1999. Cord blood leptin concentrations in relation to intrauterine growth. *Clin. Endocrinol.* 50:177–83
222. Vettor R, De Pergola G, Pagano C, Englano P, Laudadio E, et al. 1997. Gender differences in serum leptin in obese people: relationships with testosterone, body fat distribution and insulin sensitivity. *Eur. J. Clin. Invest.* 27:1016–24
223. Vettor R, Vicennati V, Gambineri A, Pagano C, Calzoni F, Pasquali R. 1997. Leptin and the hypothalamic-pituitary-adrenal axis activity in women with different obesity phenotypes. *Int. J. Obes.* 21:708–11
224. Vicennati V, Gambineri A, Calzoni F, Casimirri F, Macor C, et al. 1998. Serum leptin in obese women with polycystic ovary syndrome is correlated with body weight and fat distribution but not with androgen and insulin levels. *Metabolism* 47:988–92
225. Vuagnat BA, Pierroz DD, Lalaoui M, Englano P, Pralong FP, et al. 1998. Evidence for a leptin-neuropeptide Y axis for the regulation of growth hormone secretion in the rat. *Neuroendocrinology* 67:291–300
226. Wabitsch M, Blum WF, Muehe R, Braun M, Hube F, et al. 1997. Contribution of androgens to the gender difference in leptin production in obese children and adolescents. *J. Clin. Invest.* 100:808–13
227. Wabitsch M, Jensen PB, Blum WF, Christoffersen CT, Englano P, et al. 1996. Insulin and cortisol promote leptin production in cultured human fat cells. *Diabetes* 45:1435–38
228. Wade GN, Lempicki RL, Panicker AK, Frisbee RM, Blaustein JD. 1997. Leptin facilitates and inhibits sexual behavior in female hamsters. *Am. J. Physiol.* 272:R1354–58
229. Wand GS, Schumann H. 1998. Relationship between plasma adrenocorticotropin, hypothalamic opioid tone, and plasma leptin. *J. Clin. Endocrinol. Metab.* 83:2138–42

230. Wang J, Liu R, Hawkins M, Barzilai N, Rossetti L. 1998. A nutrient-sensing pathway regulates leptin gene expression in muscle and fat. *Nature* 393:684–88
231. Wang J, Liu R, Liu L, Chowdhury R, Barzilai N, et al. 1999. The effect of leptin on Lep expression is tissue-specific and nutritionally regulated. *Nat. Med.* 5:895–99
232. Wang MY, Lee Y, Unger RH. 1999. Novel form of lipolysis induced by leptin. *J. Biol. Chem.* 274:17541–44
- 232a. Wang T, Hartzell D, Rose B, Flatt WP, et al. 1999. Metabolic responses to intracerebroventricular leptin and restricted feeding. *Physiol. Behav.* 65: 839–48
233. Wang Y, Kuropatwinski KK, White DW, Hawley TS, Hawley RG, et al. 1997. Leptin receptor action in hepatic cells. *J. Biol. Chem.* 272:16216–23
234. Wang ZW, Zhou YT, Lee Y, Higa M, Kalra SP, Unger RH. 1999. Hyperleptinemia depletes fat from denervated fat tissue. *Biochem. Biophys. Res. Commun.* 260:653–57
235. Weigle DS, Duell PB, Connor WE, Steiner RA, Soules MR, Kuijper JL. 1997. Effect of fasting, refeeding, and dietary fat restriction on plasma leptin levels. *J. Clin. Endocrinol. Metab.* 82:561–65
236. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. 1997. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. *Proc. Natl. Acad. Sci. USA* 94:2557–62
237. Yu WH, Kimura M, Walczewska A, Karanth S, McCann SM. 1997. Role of leptin in hypothalamic-pituitary function. *Proc. Natl. Acad. Sci. USA* 94:1023–28
238. Zhang F, Basinski MB, Beals JM, Briggs SL, Churgay LM, et al. 1997. Crystal structure of the obese protein leptin-E100. *Nature* 387:206–9
239. Zhang HH, Kumar S, Barnett AH, Eggo MC. 1999. Intrinsic site specific differences in the expression of leptin in human adipocytes and its autocrine effects on glucose uptake. *J. Clin. Endocrinol. Metab.* 84:2550–56
240. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. 1994. Positional cloning of the mouse obese gene and its human homologue. *Nature* 372:425–32
241. Zhao AZ, Bornfeldt KE, Beavo JA. 1998. Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. *J. Clin. Invest.* 102:869–73
242. Zhou J, Yan X, Ryan DH, Harris RBS. 1999. Sustained effects of repeated restraint stress on muscle and adipocyte metabolism in high fat-fed rats. *Am. J. Physiol.* 277:R757–66
243. Zimmet PZ, Collins VR, de Courten MP, Hodge AM, Collier GR, et al. 1998. Is there a relationship between leptin and insulin sensitivity independent of obesity? A population-based study in the Indian Ocean nation of Mauritius. Mauritius NCD Study Group. *Int. J. Obes.* 22:171–77
244. Zumbach MS, Boehme MW, Wahl P, Stremmel W, Ziegler R, Nawroth PP. 1997. Tumor necrosis factor increases serum leptin levels in humans. *J. Clin. Endocrinol. Metab.* 82:4080–82



CONTENTS

From Chick Nutrition to Nutrition Policy, <i>D. M. Hegsted</i>	1
The Behavioral Determinants Of Exercise: Implications for Physical Activity Interventions, <i>Nancy E. Sherwood, Robert W. Jeffery</i>	21
Leptin---Much More Than a Satiety Signal, <i>Ruth B. S. Harris</i>	45
Physiological and Nutritional Regulation of Enzymes of Triacylglycerol Synthesis, <i>Rosalind A. Coleman, Tal M. Lewin, Deborah M. Muoio</i>	77
Regulation of Metabolism and Body Fat Mass by Leptin, <i>Clifton A. Baile, Mary Anne Della-Fera, Roy J. Martin</i>	105
Iron Transport, <i>Marianne Wessling-Resnick</i>	129
Biosynthesis of Vitamin B2 (Riboflavin), <i>A. Bacher, S. Eberhardt, M. Fischer, K. Kis, G. Richter</i>	153
Apolipoprotein B: mRNA Editing, Lipoprotein Assembly, and Presecretory Degradation, <i>Nicholas O. Davidson, Gregory S. Shelness</i>	169
Intestinal Transport During Fasting and Malnutrition, <i>Ronaldo P. Ferraris, Hannah V. Carey</i>	195
Dietary Fat and Breast Cancer, <i>Marion M. Lee, Scarlett S. Lin</i>	221
Calcium in Pregnancy and Lactation, <i>Ann Prentice</i>	249
Retention of Iron by Infants, <i>Samuel J. Fomon, Steven E. Nelson, Ekhard E. Ziegler</i>	273
Cellular Copper Transport and Metabolism, <i>Edward D. Harris</i>	291
Dietary Regulation of Intestinal Gene Expression, <i>I. R. Sanderson, S. Naik</i>	311
Mitochondrial Uncoupling Proteins in Energy Expenditure, <i>Leslie P. Kozak, Mary-Ellen Harper</i>	339
Molecular Mechanisms Regulating Hormone-Sensitive Lipase and Lipolysis, <i>Cecilia Holm, Torben Østerlund, Henrik Laurell, Juan Antonio Contreras</i>	365
Alcohol: Its Metabolism and Interaction with Nutrition, <i>Charles S. Lieber</i>	395
Fatty Acids and Immune Responses---A New Perspective in Searching for Clues to Mechanism, <i>Daniel Hwang</i>	431
Protein and Amino Acid Metabolism During and After Exercise and the Effects of Nutrition, <i>Michael J. Rennie, Kevin D. Tipton</i>	457
Diet and Apoptosis, <i>Walter H. Watson, Jiyang Cai, Dean P. Jones</i>	485
The Extracellular Ca ²⁺ -Sensing Receptor (CaR): Central Mediator of Systemic Calcium Homeostasis, <i>Edward M. Brown</i>	507
Transcriptional Control of Adipogenesis, <i>Shamina M. Rangwala, Mitchell A. Lazar</i>	535
The Health Benefits of Wine, <i>J. Bruce German, Rosemary L. Walzem</i>	561
Environment and Contaminants in Traditional Food Systems of Northern Indigenous Peoples, <i>H. V. Kuhnlein, H. M. Chan</i>	595
Iron Regulatory Proteins and the Molecular Control of Mammalian Iron Metabolism, <i>Richard S. Eisenstein</i>	627
The Role of the Microsomal Triglyceride Transfer Protein in Abetalipoproteinemia, <i>N. Berriot-Varoqueaux, L. P. Aggerbeck, M.-E. Samson-Bouma, J. R. Wetterau</i>	663

